All In Biotech

Drug Trial Radar · NCT06771622

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Phase Ib/IIa, Open-label, Multicenter, Dose Escalation, and Dose Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Mar 13, 2025

Primary completion

Jan 1, 2028

Study completion Jan 1, 2029

Sponsor

Lead sponsor
FBD Biologics LimitedIndustry
Sponsor type
Industry
First posted
Jan 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a non-randomized, open-label, dose-escalation, and dose-expansion Phase Ib/IIa study to evaluate the safety, tolerability, PK, PD, and preliminary antitumor activity of HCB101 administered in combination with standard or approved anticancer therapies in subjects with advanced solid tumors. The trial includes a Part-I (Phase Ib) of the dose-escalation phase and a Part-II (Phase IIa) of the dose-expansion phase. Part-I: Dose-escalation phase (Phase Ib): Part I uses a standard 3+3 dose-escalation design to characterize safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of HCB101 when administered in combination regimens. The study includes 14 planned cohorts (Cohorts 1-9, including sub-cohorts 3a-3d and 6a-6c). Part-II: Dose-expansion phase (Phase IIa) Based on safety, tolerability, PK/PD, and emerging antitumor activity observed in Part-I (Phase Ib), selected dose levels, tumor types, and combination regimens will be further investigated in Part-II (Phase IIa).

Conditions

  • Solid Cancer

Interventions

  • HCB101Drug

    QW

  • TrastuzumabDrug

    8 mg/kg IV loading dose on Day 1 of cycle 1, then 6 mg/kg IV every 21 days;

  • PertuzumabDrug

    840 mg IV on Day 1, cycled every 21 days;

  • OxaliplatinDrug

    130 mg/m2 IV on Day 1, cycled every 21 days

  • CapecitabineDrug

    1000 mg/m2 PO BID on Days 1-14, Cycled every 21 days

  • RamucirumabDrug

    8 mg/kg IV on Days 1 and 15, Cycled every 28 days

  • PaclitaxelDrug

    80 mg/m2 IV on Days 1, 8, and 15, Cycled every 28 days

  • BevacizumabDrug

    5 mg/kg IV on Day 1, Repeat every 2 weeks;

  • CetuximabDrug

    400 mg/m2 first infusion, followed by 250 mg/m2 IV weekly;

  • IrinotecanDrug

    180 mg/m2 IV over 30-90 minutes on Day 1 every 2 weeks

  • LeucovorinDrug

    400 mg/m2 IV on Day 1 every 2 weeks

  • 5-FUDrug

    400 mg/ m2 IV bolus on Day 1, followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion Repeat every 2 weeks

  • ToripalimabDrug

    240 mg/kg IV on Day 1 Cycled every 21 days

  • Albumin-bound paclitaxelDrug

    125 mg/m2 IV on day 1 and Day 8 Cycled every 21 days

  • PembrolizumabDrug

    200 mg IV day 1; given every 21 days

  • Carboplatin (AUC 5)Drug

    AUC=5, IV on D1, Q3W for 4\~6 cycles

  • EtoposideDrug

    100mg/m2, IV on D1, 2, 3, Q3W for 4\~6 cycles

  • AtezolizumabDrug

    1200 mg IV on D1, Q3W

  • Trastuzumab deruxtecanDrug

    5.4 mg/kg IV on D1, Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number/incidence and percentage of subjects with adverse events.Time frame: 12 months
  2. Number of subjects with Maximal tolerance dose (MTD) of HCB101Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.